Last
Update:
March 25, 2018
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Videos
-
HIV/HCV Therapy: Drug Interactions with the new
DAA regimens
BC
Centre for Excellence in HIV/AIDS |
|
|
Journal Papers, Abstracts,
and Commentaries
|
| |
|
Rates of sustained virological response 12 weeks after the
scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV)
therapy from the National German HCV registry: does HIV coinfection impair
the response to DAA combination therapy?
Bischoff J, Mauss S, Cordes C, et al
HIV Med. 2018 Jan 25.
Abstract
Direct-Acting Antivirals Improve Access to Care and Cure for Patients With
HIV and Chronic HCV Infection.
Collins LF, Chan A, Zheng J,
et al
Open Forum Infect Dis. 2017
Dec 9;5(1):ofx264.
Abstract
FULL-TEXT ARTICLE
Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV
co-infected patients receiving directly-acting antivirals.
Rozera G, Fabbri G, Lorenzini P, et al
|n
PLoS One. 2017 Oct 27;
Paper
HCV-infected and HIV/HCV co-infected individuals treated with
direct-acting antivirals: to what extent do they differ?
Bruno G, Saracino A, Scudeller
L,
et al
Int J Infect Dis.
2017 Jul 17
Abstract
Occurrence of hepatocellular carcinoma in HIV/HCV co-infected
patients treated with direct-acting antivirals.
Hasson H, Merli M, Messina E,
J
Hepatol. 2017 Apr 11.
Abstract
Interferon-free regimens improve portal hypertension and
histological necroinflammation in HIV/HCV patients with advanced liver
disease.
Schwabl P, Mandorfer M, Steiner S, et al
Aliment Pharmacol Ther. 2017
Jan;45(1):139-149
Abstract
Clinically Significant Drug-Drug Interactions Between Hepatitis C
Virus and HIV Treatments.
Kiser JJ.
Top Antivir Med. 2016
Oct/Nov;24(3):106-110.
Abstract
Direct-acting antivirals in hepatitis C virus (HCV)-infected and
HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L, Lai A, Calvi
E, et al
HIV Med. 2016 Aug 1
Abstract
HIV and HCV Therapies in 2015: Optimal Regimens.
Sasadeusz J.
AIDS Rev.
2016 Jul 19;18(4).
Abstract
High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in
HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C, Grant J, Ammerman LR
J Antimicrob Chemother. 2016 Jun 20.
Abstract
All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient
and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort.
Sogni P, Gilbert C, Lacombe K, Piroth L,
et al
Clin Infect Dis. 2016
Jun 17.
Abstract
Marked decrease in lymphocyte count in HIV/HCV co-infected patients with
advanced liver disease during anti-HCV treatment with direct-acting antiviral
regimens including ribavirin.
Merli M, Messina E, Salpietro S,
et al
Clin Infect Dis. 2015 Oct
27. pii: civ902.
Abstract
FULL-TEXT ARTICLE
Potential for Drug-Drug Interactions between Antiretrovirals and HCV
Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected
Patients.
Poizot-Martin I, Naqvi A, Obry-Roguet V,
et al
PLoS One. 2015 Oct
21;10(10):e0141164.
.
Paper |
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
Wyles DL.
Clin Liver Dis. 2015
Nov;19(4):689-706.
.
Abstract
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side
effects.
Esposito I, Labarga P, Barreiro P, et al
Expert Opin Drug Saf.
2015 Sep;14(9):1421-34.
Abstract
Direct-acting antiviral-based therapy for chronic hepatitis C virus in
HIV-infected patients.
Del Bello D, Ita Nagy F, et al
Curr Opin HIV AIDS. 2015
Sep;10(5):337-47. .
Abstract
Key drug-drug interactions with direct-acting antiviral in
HIV-HCV coinfection.
El-Sherif O, Khoo S, Solas C
Curr Opin HIV AIDS. 2015
Sep;10(5):348-54.
Abstract
Drug Interactions of Hepatitis C Direct-Acting Antivirals in the
HIV-Infected Person.
El-Sherif O, Back D.
Curr HIV/AIDS Rep.
2015
Jul 11
Abstract
Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to
Accommodate Direct Acting Antivirals.
Cope R, Pickering A, Glowa T, et al
AIDS Patient Care STDS. 2015 Jul;29(7):379-83.
Abstract
Optimal therapy of HIV/HCV co-infected patients with direct acting
antivirals.
Rockstroh JK.
Liver Int. 2015 Jan;35 Suppl s1:51-55.
Abstract
Latest pharmacotherapy options for treating hepatitis C in
HIV-infected patients.
Macías J, Neukam K, Merchante N, Pineda JA.
Expert Opin Pharmacother. 2014 Aug 1:1-12.
Abstract
Managing drug-drug interactions in an HIV-infected patient
receiving antiretrovirals, anti-HCV therapy and carbamazepine: A 'tour de force'
for clinical pharmacologists.
Burger DM, Arends JE, Jacobs BS, et al
Int J Antimicrob Agents.
2014 May 9. .
Abstract
Drug interactions between antiretrovirals and new or emerging
direct-acting antivirals in HIV/hepatitis C virus coinfection.
Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH.
Curr Opin Infect Dis. 2014
Feb;27(1):36-45.
Abstract
The progression of liver fibrosis in prison
inmates co-infected by HIV and HCV who started on boosted protease inhibitor
therapy.
Saiz de la Hoya Zamácola P, Alía Alía C, et al
Rev Esp Sanid Penit.
2013 Oct;15(2):54-62.
Abstract
A review of pharmacological interactions between HIV or
hepatitis C virus medications and opioid agonist therapy: implications and
management for clinical practice.
Bruce RD, Moody DE, Altice FL, et al
Expert Rev Clin Pharmacol.
2013 May;6(3):249-69.
Abstract
Focus on drug interactions: the challenge of treating hepatitis C
virus infection with direct-acting antiviral drugs in the HIV-positive
patient.
Rodríguez-Torres M.
Curr Opin Infect Dis.
2013 Feb;26(1):50-7
Abstract |
Hepatotoxicity of antiretrovirals in patients with human immunodeficiency virus
and viral hepatitis coinfections.
Parenti P, Marconi L, Lupo S.
J Int AIDS Soc. 2012 Nov
11;15(6):18431
Abstract
Using phosphazide in regimes of ART in patients co-infected with HIV and HCV
receiving treatment of hepatitis.
Kravchenko A, Kanestri V, Kuimova U,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18430.
Abstract
Who needs direct acting antivirals for HCV? Challenges faced in
advancing HCV therapy for HIV-HCV co-infected persons.
Klein MB, Rollet KC, Hull M, et al
Antivir Ther. 2012 Dec 4.
.
Abstract
How important is HIV therapy for preventing liver fibrosis
progression in HIV-HCV-coinfected individuals?
Rockstroh JK
Antivir
Ther. 2012 Oct 10.
Abstract
Antiretroviral therapy and sustained virological response to HCV therapy are
associated with slower liver fibrosis
progression in HIV-HCV-coinfected patients: study from the ANRS CO
13 HEPAVIH cohort.
Loko MA, Bani-Sadr F, Valantin MA,et
al
Antivir Ther. 2012 Oct 10.
Abstract
Antiviral drug advances in the treatment of human
immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV).
Wegzyn CM, Wyles DL.
C
urr Opin Pharmacol. 2012 Jul 5.
Abstract
Hepatitis
C and HIV Co-Infection: New Drugs in Practice and in the Pipeline.
Jennings CL, Sherman KE.
Curr HIV/AIDS Rep. 2012 May 26.
Abstract |
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Conference
Reports, Abstracts, and Posters
|
Journal Papers, Abstracts, and Commentaries
|
|
Journal
Papers, Abstracts, and Commentaries |
| |
| |
Boceprevir and Antiretroviral Pharmacokinetic
Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials
Group Study A5309s.
Kiser JJ, Lu D, Rosenkranz SL, Morse GD, et al
Drugs R D. 2017
Sep 5
Abstract
Boceprevir and Antiretroviral Pharmacokinetic Interactions in
HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study
A5309s.
Kiser JJ, Lu D, Rosenkranz SL,
Drugs R D. 2017 Sep
5
Abstract
Boceprevir plus Peginterferon/Ribavirin to retreat HCV genotype-1 in
HIV-HCV coinfected patients. Final results of BOC HIV-HCV Spanish
Study.
Laguno M, Von Wichmann
MA, Van den Eynde E,
Int J Infect Dis.
2016 Nov 1.
Abstract
Addition of boceprevir to PEG-interferon/ribavirin in
HIV-HCV-Genotype-1-coinfected, treatment-experienced patients:
efficacy, safety, and pharmacokinetics data from the ANRS HC27
study.
Poizot-Martin I, Bellissant E,
et al
HIV Clin Trials.
2016 Mar;17(2):63-71
Abstract
Favourable SVR12 rates with boceprevir or telaprevir triple therapy
in HIV÷ HCV coinfected patients.
Arends JE, van der Meer JT,
Posthouwer D, et al
Neth J Med.
2015 Aug;73(7):324-30.
Abstract
FULL-TEXT ARTICLE
Boceprevir or Telaprevir Based Triple Therapy against Chronic
Hepatitis C in HIV Coinfection- Real-Life Safety and Efficacy
Neukam K, Munteanu DI, Rivero-Juárez A, et al
PLoS One. 2015
Apr 29;10(4):e0125080.
Paper
Triple therapy with boceprevir or telaprevir in a European cohort of
cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P, Gilbert C, Lacombe K, et al
Liver Int.
2015 Feb 4
Abstract
Boceprevir and telaprevir-based regimens for the
treatment of hepatitis C virus in HIV/HCV coinfected patients.
Beste LA, Green PK, Ioannou GN.
Eur J Gastroenterol Hepatol.
2015 Feb;27(2):123-9
Abstract
Drug-drug interactions of telaprevir and boceprevir
in HCV-monoinfected and HIV/HCV-coinfected patients can modify the
adherence.
Gonzalez-Colominas
E, Broquetas T, et al
Liver Int. 2014 Nov
10.
Abstract
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus
co-infected patients to treat recurrence of hepatitis C virus
infection after liver transplantation.
Antonini TM, Furlan V, Teicher E,
et al
AIDS. 2014
Nov 9
Abstract
Response-guided Boceprevir-based Triple-Therapy in HIV/HCV-coinfected
Patients: The HIVCOBOC-RGT Study.
Mattias M, Sebastian S, Philipp S, et al
J Infect Dis. 2014 Sep 11
Abstract
Pharmacokinetic Interaction between Boceprevir and Etravirine in
HIV/HCV Seronegative Volunteers.
Hammond KP, Wolfe P, Burton JR Jr, :
J Acquir Immune Defic Syndr.
2012 Oct 15
Abstract
HIV-HCV co-infection facing HCV protease inhibitor licensing:
implications for clinicians.
Ingiliz P, Rockstroh JK.
Liver Int.
2012 Apr 17
Abstract| |
|
Journal Papers, Abstracts, and Commentaries
|
|
Journal Papers, Abstracts,
and Commentaries |
| |
| |
Generic daclatasvir plus sofosbuvir, with or without ribavirin,
in treatment of chronic hepatitis C: real-world results from 18 378 patients in
Egypt
Omar H, El Akel W, Elbaz T, et al
Aliment Pharmacol Ther.
2017 Nov 29.
Abstract
Biliary and kidney lithiasis during treatment with
daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine
in an HIV/HCV genotype 4-infected patient: a case report.
Vavassori A, Lanza P, Izzo I, Casari S, et a
lRecenti
Prog Med. 2017
Feb;108(2):98-100.
Abstract
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and
ribavirin in previously untreated HCV subjects coinfected with HIV and HCV
genotype-1: a Phase III, open-label study.
Sulkowski MS, Fessel WJ, Lazzarin A, et al
Hepatol Int. 2017 Feb 16
Abstract
Successful treatment of three patients with human immunodeficiency virus and
hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
Hirashima N, Iwase H, Shimada M,
Clin J Gastroenterol. 2016 Oct 20.
Abstract
Daclatasvir plasma level and resistance selection in HIV patients with HCV
cirrhosis treated with daclatasvir, sofosbuvir and ribavirin.
Parisi SG, Loregian A, Andreis S,
et
al
Int J Infect Dis.
2016 Jul 1.
Abstract
Non-response to daclatasvir and asunaprevir therapy in patients co-infected with
hepatitis C virus genotypes 1 and 2.
Sohda T, Yamauchi E, Anan A,
et al
Hepatol Res. 2016 Jun 4.
Abstract
Removal from liver transplantation list of an hepatitis C virus-HIV co-infected
patient after successful treatment with sofosbuvir and daclatasvir
Llaneras J, Castells L, Santos B,
et al
Transpl Infect Dis.
2016 Apr 2.
Abstract
12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection
(ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF, McDonald C, Ramgopal M,
et al
Clin Infect Dis. 2016 Mar
29.
Abstract
Daclatasvir and Asunaprevir for Recurrent Hepatitis C following
Living-Donor Liver Transplantation with Human Immunodeficiency Virus
Coinfection.
Tanaka T, Akamatsu N, Kaneko J,
et al
Hepatol Res. 2015 Oct 27.
Abstract
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with
HIV-1.
Wyles DL, Ruane PJ, Sulkowski MS, et al
N Engl J Med. 2015 Jul 21.
Abstract
High cure rate with 24 weeks of
daclatasvir-based
quadruple therapy in treatment-experienced null-responder HIV/HCV
genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
Piroth L,
Paniez H, Taburet AM, et al
Clin Infect Dis.
2015 May 14.
Abstract |
Conference
Reports, Abstracts, and Posters
Journal Papers, Abstracts,
and Commentaries
|
Journal Papers, Abstracts,
and Commentaries
|
Journal Papers, Abstracts,
and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts,
and Commentaries
|
| |
STARTVerso4: faldaprevir and pegylated interferon α-2a/ribavirin in
individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D, Nelson M, Soriano V, et al
AIDS. 2015 Jan 21
Abstract
Clinical assessment of potential drug interactions of faldaprevir, a
hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz
and tenofovir.
Sabo
JP, Kort J, Ballow C, Haschke M,
et al
Clin Infect Dis. 2014
Aug 4.
Abstract
Faldaprevir (BI 201335) for the treatment of
hepatitis C in patients co-infected with HIV.
Laufer NL, Rockstroh JK.
Expert Rev Anti Infect Ther. 2014 Feb;12(2):157-64.|
Abstract |
Journal Papers, Abstracts,
and Commentaries
|
Journal Papers, Abstracts,
and Commentaries
|
Journal Papers, Abstracts, and Commentaries
|
Journal Papers, Abstracts,
and Commentaries
|
| |
Sustained virologic response to standard interferon or pegylated
interferon and ribavirin in patients with hepatitis C virus genotype 5:
systematic review and meta-analysis of ten studies and 423 patients.
Devaki P, Jencks D, Yee BE, Nguyen MH.
Hepatol Int. 2015 May 28.
Abstract
Thrombotic thrombocytopenic purpura associated with interferon therapy in a HIV
and HCV co-infected woman.
Michaux C, Randrianasolo D,
Vandenhende MA, et al
Rev Med Interne.
2013 May 9.
Abstract
Clinical Effects of Viral Relapse after Interferon Plus Ribavirin
in Patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
Berenguer J, Alvarez-Pellicer J, Carrero A, et alJ
Hepatol. 2013 Feb 7
Abstract
Depressive disorders in HIV-HCV patients undergoing interferon-α
treatment for hepatitis C.
Fialho R, Eccles J, Keller M, , et al
J Int AIDS Soc. 2012 Nov 11;15(6):18425
Abstract
Insulin Resistance Impairs Response to Interferon Plus Ribavirin
in Patients Coinfected
With HIV and Hepatitis C Virus.
Ryan P, Resino S, Miralles P, et al
J Acquir Immune Defic Syndr.
2010 Jun 23
Abstract |
|
HIV/HCV
Main
Page
Abacavir